# A Study to Assess Safety and Efficacy of Avalglucosidase Alfa Administered Every Other Week in Pediatric Patients With Infantile-onset Pompe Disease Previously Treated With Alglucosidase Alfa

> **NCT03019406** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Genzyme, a Sanofi Company** · enrollment: 22 (actual)

## Conditions studied

- Glycogen Storage Disease Type II-Pompe's Disease

## Interventions

- **DRUG:** Avalglucosidase alfa (GZ402666)
- **DRUG:** Alglucosidase alfa (GZ419829)

## Key facts

- **NCT ID:** NCT03019406
- **Lead sponsor:** Genzyme, a Sanofi Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2017-10-12
- **Primary completion:** 2019-09-30
- **Final completion:** 2027-08-10
- **Target enrollment:** 22 (ACTUAL)
- **Last updated:** 2026-01-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03019406

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03019406, "A Study to Assess Safety and Efficacy of Avalglucosidase Alfa Administered Every Other Week in Pediatric Patients With Infantile-onset Pompe Disease Previously Treated With Alglucosidase Alfa". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT03019406. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*